Astrazeneca (AZN) Total Liabilities (2016 - 2026)

Astrazeneca has reported Total Liabilities over the past 17 years, most recently at -$66.6 billion for Q1 2026.

For Q1 2026, Total Liabilities fell 2.32% year-over-year to -$66.6 billion; the TTM value through Mar 2026 reached -$66.6 billion, down 2.32%, while the annual FY2025 figure was -$65.4 billion, 203.47% down from the prior year.
Total Liabilities for Q1 2026 was -$66.6 billion at Astrazeneca, down from -$65.4 billion in the prior quarter.
Over five years, Total Liabilities peaked at $63.2 billion in Q4 2024 and troughed at -$68.5 billion in Q3 2025.
A 5-year average of -$41.5 billion and a median of -$63.9 billion in 2022 define the central range for Total Liabilities.
Biggest five-year swings in Total Liabilities: grew 12.3% in 2022 and later crashed 203.47% in 2025.
Year by year, Total Liabilities stood at $59.4 billion in 2022, then rose by 4.25% to $62.0 billion in 2023, then increased by 1.95% to $63.2 billion in 2024, then crashed by 203.47% to -$65.4 billion in 2025, then fell by 1.95% to -$66.6 billion in 2026.
Business Quant data shows Total Liabilities for AZN at -$66.6 billion in Q1 2026, -$65.4 billion in Q4 2025, and -$68.5 billion in Q3 2025.

Peer Comparison